CURE vs XLVX: Leverage, Returns & Decay

Over three months to Nov 13, 2026, against its daily multiple, compounded, CURE finished 3.3 points short and XLVX 2.9 points short.

Return gap
+14.0 pts3 months to Nov 13, 2026: CURE ahead, total return
Fee gap
0.49 ptsA year: CURE 0.94%, XLVX 0.45%, per filings dated Mar 3, 2026 and Jun 11, 2026
Overlap
–No book read for both funds
Net flow
–Needs daily flows for both funds
The answerOne drawing that carries it.

Compare two other funds

The evidenceWhy, in charts and cards.
CURE and XLVX · 3 months

Growth of 100

CURE +38.2%XLVX +24.2%
Growth of 100 in CURE and XLVX over 3 months, Aug 14, 2026 to Nov 13, 2026, with distributions reinvested. CURE ends at 138.2 (+38.2%), XLVX at 124.2 (+24.2%).

CURE +38.2%, XLVX +24.2%: CURE +14.0 pts ahead, 3 months, Aug 14, 2026 to Nov 13, 2026.

Share

Use this comparison

Client brief

No client brief for this pair: ETFIQ prints no one-year total return for XLVX.

Alert

CURE flows, by email on Sundays.

One-click unsubscribe. See Privacy.

Hypothetical · drag to set

Fees over time

Hypothetical. $10,000 in CURE for 10 years at 0.94% a year costs about $1,526 in fees and lost growth; XLVX at 0.45% would cost $746. Assumes 6% a year before fees, a sample rate, not a forecast.

How each fund moved

CURE · 3 months to Nov 13, 20261.7 pts short of its stated multiple
1.7 pts short of its stated multipleCURE returned +38.2% while 3 times XLV's move would have been +39.9%. Data from Aug 14, 2026 to Nov 13, 2026.XLV +13.3% ×3 implies+39.9%CURE returned+38.2%1.7 pts short of its stated multipleCURE returned +38.2% while 3 times XLV's move would have been +39.9%. Data from Aug 14, 2026 to Nov 13, 2026.XLV +13.3% ×3 implies+39.9%CURE returned+38.2%

CURE returned +38.2% while 3 times XLV's move would have been +39.9%. Data from Aug 14, 2026 to Nov 13, 2026.

Data from Aug 14, 2026 to Nov 13, 2026.
XLVX · 3 months to Nov 13, 20262.4 pts short of its stated multiple
2.4 pts short of its stated multipleXLVX returned +24.2% while 2 times XLV's move would have been +26.6%. Data from Aug 14, 2026 to Nov 13, 2026.XLV +13.3% ×2 implies+26.6%XLVX returned+24.2%2.4 pts short of its stated multipleXLVX returned +24.2% while 2 times XLV's move would have been +26.6%. Data from Aug 14, 2026 to Nov 13, 2026.XLV +13.3% ×2 implies+26.6%XLVX returned+24.2%

XLVX returned +24.2% while 2 times XLV's move would have been +26.6%. Data from Aug 14, 2026 to Nov 13, 2026.

XLVX returned +24.2% while 2 times XLV's move would have been +26.6%. Data from Aug 14, 2026 to Nov 13, 2026.

IQ Leverage Score

How closely it delivered its daily multiple over 3 months, ranked against 31 leveraged ETFs at 3x, over three months and 498 leveraged ETFs at 2x, over three months. 100 is best.

XLVX scores higher · Did it keep up with its own daily multiple, compounded day by day, over three months?

CURE among the 31 leveraged ETFs at 3x, over three months

1.6, the lowest in this set98.4, the highest

XLVX among the 498 leveraged ETFs at 2x, over three months

0.1, the lowest in this set99.9, the highest

A percentile among the 31 leveraged ETFs at 3x, over three months. XLVX is a percentile among the 498 leveraged ETFs at 2x, over three months, a different set, so the two marks are not on one scale. Three months only, against the fund's own daily multiple; a different quarter can rank it very differently.

Key numbers

CURE returned, 3 months
+38.2%
XLVX returned, 3 months
+24.2%
CURE from its stated multiple: compounding +1.6 pts, gap to the daily multiple −3.3 pts
−1.7 pts
XLVX from its stated multiple: compounding +0.5 pts, gap to the daily multiple −2.9 pts
−2.4 pts

XLVX costs 0.49 points a year less; CURE is far larger, $209m against $1.8m.

Pair scorecard

Open the table

Points (pts) are percentage points.

Total return, 1 year+65.7%not published
What its daily multiple gave, 3 months41.5%27.1%
What the underlying did, 3 monthsXLV 13.3%XLV 13.3%
What the underlying did, 3 monthsXLV 13.3%XLV 13.3%
What it tracksHealthcareU.S. Healthcare
Expense ratio0.94%0.45%
Net assets, as of Nov 12, 2026$209m$1.8m
Holdings in commonnot published

The numbers behind it

Net assets: $209m on Nov 12, 2026 for Direxion Daily Healthcare Bull 3X ETF, and $1.8m on Nov 13, 2026 for Corgi U.S. Healthcare 2x Daily ETF.

Side by side

Open the table
FundDirexion Daily Healthcare Bull 3X ETF · Aims to return three times the daily move of health care (XLV)Corgi U.S. Healthcare 2x Daily ETF · Aims to return twice the daily move of health care (XLV)
IssuerDirexionCorgi
Sets out to return+3x+2x
Underlying assetXLVXLV
Segmentsectorsector
Fund returned, 3 months+38.2%+24.2%
Underlying returned, over that window+13.3%+13.3%
What the stated multiple implies, over that window+39.9%+26.6%
Difference from stated, over that window−1.7 pts−2.4 pts
Fund returned, 1 year+65.7%+57.1% (since launch, Jun 3, 2026)
Difference from stated, over that window−11.4 pts−0.9 pts (since launch, Jun 3, 2026)
Underlying volatility19%19%
Difference over the days both have tradedno shared window−2.4 pts
Expense ratio0.94%0.45%
First tradedJun 15, 2011Jun 3, 2026
Net assets, CURE as of Nov 12, 2026 and XLVX as of Nov 13, 2026$209m$1.8m

As of Nov 13, 2026. Source: ETFIQ.

The dataFull tables, method and files, one click away.

Window by window

Open the full table
1 month+25.9%+16.3%+25.8%+17.2%+0.1 pts−0.9 pts
3 months+38.2%+24.2%+39.9%+26.6%−1.7 pts−2.4 pts
6 months+104.8%–+93.6%–+11.2 pts–
1 year+65.7%–+77.1%–−11.4 pts–
3 years+117.4%–+165.6%–−48.2 pts–
Since launch (Not the same days: CURE Jun 2011 · XLVX Jun 2026)+3,894.1%+57.1%not meaningful+58.0%not meaningful−0.9 pts

– means no data for this window.

From Jun 2026 to Nov 2026, CURE returned more: +71.0% to +44.1%. XLVX fell less at its worst: −10.9% to −15.8%.

Jun 12, 2026 to Nov 12, 2026 · 22 weekly returns · 3 measures

Full scorecard

Open the full table
Total return+71.0%+44.1%CUREPrice change plus distributions, reinvested.
Price return+70.0%+44.1%CUREPrice change alone, distributions left out.
Max drawdown−15.8%−10.9%XLVXDeepest fall from a high to the low after it.
More

Computed by ETFIQ from Tiingo daily prices and ETFIQ's distribution records, 22 weekly returns. Cash rate: the 13-week Treasury bill.

About CURE

Over the three months to Nov 13, 2026, CURE returned 38.2%, against 41.5% for three times XLV's daily moves. Read the multiple against the whole window instead and 3 times XLV's 13.3% implies +39.9%, which makes CURE look 1.7 points short. That is not the fund's objective, which is daily. Of that 1.7, daily compounding is +1.6 points, which any 3 times fund would show over the same path, and the fund itself is −3.3 points against 3 times each day's move, compounded. CURE aims to return +3 times XLV's move each day, then resets. Over one day it does that. Over longer periods the daily results compound, so the total is not +3 times the period's move: it is lower after a fall and recovery, and can be higher in a steady run. XLV moved at 19% annualized over that window. The more it moves, the further the two numbers separate.

About XLVX

Over the three months to Nov 13, 2026, XLVX returned 24.2%, against 27.1% for twice XLV's daily moves. Read the multiple against the whole window instead and 2 times XLV's 13.3% implies +26.6%, which makes XLVX look 2.4 points short. Of that 2.4, daily compounding is +0.5 points, which any 2 times fund would show over the same path, and the fund itself is −2.9 points against 2 times each day's move, compounded. XLVX aims to return +2 times XLV's move each day, then resets. Over longer periods the daily results compound, so the total is not +2 times the period's move: it is lower after a fall and recovery, and can be higher in a steady run.

Questions people ask

Which came closer to its daily multiple, CURE or XLVX?

Over the window to Nov 13, 2026, CURE finished 1.7 points from what its multiple implies and XLVX finished 2.4 points from its own, so CURE came closer. Neither number predicts the next window: it depends on how much the underlying moves about.

Are CURE and XLVX levered on the same thing?

Yes. Both are levered on health care, CURE at +3 times and XLVX at +2 times the daily move.

Which one decays faster, CURE or XLVX?

Decay follows how much the underlying moves about. Over this window CURE’s moved at 19% annualized and XLVX’s at 19%, so CURE has the rougher ride and, at the same multiple, loses more to compounding.

Can I hold CURE or XLVX for a year?

Both reset every day, so the multiple in the name applies to a single day, and daily results compound. Over a year the total is not the multiple times the year’s move; after a fall and recovery it is lower.

Which is cheaper, CURE or XLVX?

CURE charges 0.94% a year and XLVX charges 0.45%, so XLVX is cheaper. Fees come from each fund's prospectus.

Other comparisons

Sources

More

Links are sources, not endorsements. A comparison is not a recommendation.

Copy and cite

Cite this pageCitation, APA and Markdown

ETFIQ, CURE against XLVX, data as of Nov 13, 2026. https://etfiq.com/compare/leverage/cure-vs-xlvx

Open data

Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.